论文部分内容阅读
目的:探讨和分析2型糖尿病合并高血压患者的临床治疗方法及其疗效。方法:回顾性分析本院2011年12月至2014年03月收治的2型糖尿病合并高血压患者临床资料,所有患者随机分成两组,两组患者均给予常规的临床治疗和护理,观察组患者在此基础上采用厄贝沙坦进行治疗,对照组患者在常规治疗方法基础上给予安氯地平进行治疗,比较两组患者的临床疗效,不良反应以及治疗前后肾功能的变化。结果:观察组的治疗总有效率为90.16%(55/61),与对照组的81.97%(50/61)相比差异显著,具有统计学意义(P<0.05);两组的临床不良反应率分别为1.64%(1/61)、9.84%(6/61),两组差异显著,具有统计学意义(P<0.05),观察组患者治疗后肾脏功能较治疗前显著改善,与对照组比较差异极显著,具有统计学意义(P<0.05)。结论:对于2型糖尿病合并高血压患者采用厄贝沙坦进行治疗具有较好的临床疗效,与传统治疗方法相比去不良反应少,有助于患者肾脏功能的恢复,该方法值得临床推广使用。
Objective: To investigate and analyze the clinical treatment of type 2 diabetes mellitus patients with hypertension and its curative effect. Methods: The clinical data of patients with type 2 diabetes mellitus complicated with hypertension admitted from December 2011 to March 2014 in our hospital were retrospectively analyzed. All patients were randomly divided into two groups. Both groups were given routine clinical care and nursing. Patients in the observation group On this basis, irbesartan was used for treatment. Patients in the control group were treated with amlodipine on the basis of routine treatment. The clinical efficacy, side effects and changes of renal function before and after treatment were compared between the two groups. Results: The total effective rate of the observation group was 90.16% (55/61), which was significantly different from that of the control group (81.97%, 50/61) (P <0.05). The clinical adverse reactions (P <0.05). The renal function of the observation group was significantly improved after treatment compared with that of the control group, which was significantly higher than that of the control group (1.64%, 1/61) and 9.84% (6/61) The difference was significant, with statistical significance (P <0.05). Conclusion: Irbesartan for type 2 diabetes mellitus patients with hypertension has better clinical curative effect, less adverse reactions than traditional treatment methods, which is helpful to the recovery of renal function in patients with type 2 diabetes mellitus, which is worthy of clinical promotion .